<DOC>
	<DOC>NCT00864838</DOC>
	<brief_summary>The purpose of this study is to evaluate the effects of anterior chamber paracentesis, brimonidine and oral acetazolamide to reduce intra-ocular pressure variations after intravitreal bevacizumab injection.</brief_summary>
	<brief_title>Oral Acetazolamide, Brimonidine Tartarate, and Anterior Chamber Paracentesis for Ocular Hypertension Control After Intravitreal Bevacizumab</brief_title>
	<detailed_description />
	<mesh_term>Hypertension</mesh_term>
	<mesh_term>Macular Degeneration</mesh_term>
	<mesh_term>Ocular Hypertension</mesh_term>
	<mesh_term>Diabetic Retinopathy</mesh_term>
	<mesh_term>Bevacizumab</mesh_term>
	<mesh_term>Acetazolamide</mesh_term>
	<mesh_term>Brimonidine Tartrate</mesh_term>
	<criteria>Diagnosis of age related macular disease or diabetic retinopathy Able and willing to provide informed consent History of ocular hypertension or glaucoma High Myopes (&gt; 6 spherical diopters) High Hyperopes (&gt; 4 spherical diopters) Pulmonary disease Renal disease Known allergy to any component of the study drug Myocardial infarction, transient ischemic attack within 4 months prior to randomization or any contraindication for bevacizumab use</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>March 2009</verification_date>
	<keyword>intraocular pressure</keyword>
	<keyword>bevacizumab</keyword>
	<keyword>acetazolamide</keyword>
	<keyword>brimonidine</keyword>
	<keyword>anterior chamber paracentesis</keyword>
</DOC>